PR
Prime Medicine, Inc.
PRME · NASDAQ
$3.21 +7.72% (+$0.23)
1M -9.83%
Market Cap $579.8M
P/E Ratio -
Div. Yield -
ROE 188.27%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 142.35x
P/B 14.56x
P/E N/A
Growth
0 /100
Declining Book val. growth 27.43%
EPS growth N/A
FCF growth N/A
Profitability
0 /100
Weak Gross margin 1,025.61%
FCF margin 3,850.92%
Net margin 4,613.11%
Quality
0 /100
Poor ROIC 86.83%
Asset turnover 0.02x
ROE 188.27%
Debt
33 /100
High Debt/Equity 2.83x
Current ratio 3.05x
Int. coverage N/A
Stability
22 /100
Unstable Beta 2.35x
Profitable years 0
EPS volatility 40.70%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRME
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Allan Reine
Employees
146
Headquarters
Cambridge
Upcoming events
06 NOV
Earnings
Upcoming earnings report